Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
PARIS, May 11 /PRNewswire-FirstCall/ — Cellectis (Alternext: ALCLS), the French genome engineering specialist, announces today that Frederic Paques, PhD, Chief Scientific Officer, has been invited to present Cellectis’ approaches on vectors for meganucleases and genome surgery at the 13th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting to be held at the Marriott Wardman Park Hotel in Washington, USA, on May 19-22, 2010.
Targeted approaches have emerged today as an alternative to current random insertion strategies for gene therapy. Meganucleases, the most specific endonucleases, represent ideal tools for targeted genome editing, or genome surgery. They can induce up to 20% of gene insertion into chosen human genes. The entry of meganucleases into different cell types can be achieved by various means, including viral and non-viral vectorization.
Dr Paques will discuss “Meganucleases and Viral Vectors: Alternative or Complementary Approaches” on May 22, 2010, at 8:30AM, during an oral session on Special Considerations with Using Viral Vectors for Gene Modification of Stem Cells.
Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools – meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.
To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.
Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over EUR 70 million in funding since inception.
More information at www.cellectis.com
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company’s prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers (“AMF”) granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.